Mersana Therapeutics Inc (NASDAQ: MRSN) made a new high in Friday’s session. This came after the company presented at the 38th annual J.P. Morgan Healthcare Conference. Earlier in the year, the company announced a series of pipeline updates and milestones for 2020. 

Announcing some of the progress, CEO Anna Protopapas touched on XMT-1536. This is the company’s treatment targeting Dolaflexin ADC. She stated that it was close to its proof of concept and the company expects to give key data from dose expansion all through the year. She also stated that XMT-1536 had confirmed, durable stability in biomarker unselected and pre-treated patients.

On top of that, the company made a number of other updates that continue to anchor its price so far. One of those updates was on the increased dosage in the XMT-1536 phase 1 study.  The company noted that, the treatment had good tolerance at 43 mg/m2 when administered once a week. It added that it had increased dosage to 52 mg/m2 every four weeks, and that a report on data on this increase would be given within H1 of the year.

The company also announced selection of its XMT-1592. This is the company’s NaPi2b targeting Dolasynthen ADC. The company noted that, the platform maintains its proprietary Dolalock payload. It also showed some additional benefits including site-specific conjugation, higher hydrophilicity and more accurate drug-to-antibody ratio.

On top of that, it announced that, it was starting IND-enabling studies on B7-H4, its top candidate on tumor-associated macrophages and tumor cells. The company announced that in pre-clinical studies, B7-H4 had been shown to put direct cytotoxic effect through tumor cells.

From its price action, MRSN surged higher on Friday and hit highs of $8.93 before closing at $8.05. Volumes in the day stood at 2.48 million.

About Mersana Therapeutics Inc

Mersana Therapeutics Inc is a biopharma company that develops cancer treatments. It is headquartered in Cambridge, Massachusetts.